Enanta Pharmaceuticals
ENTA
99 hedge funds and large institutions have $419M invested in Enanta Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 46 increasing their positions, 23 reducing their positions, and 9 closing their positions.
189% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 9
155% more capital inflows, than outflows
Capital inflows: $77.9M | Capital outflows: $30.5M
100% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 23
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
21% more funds holding
Funds holding: 82 → 99 (+17)
15% more call options, than puts
Call options by funds: $1.35M | Put options by funds: $1.17M
6.6% more ownership
Funds ownership: 45.84% → 52.44% (+6.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Consonance Capital Management
New York
|
+$11.1M |
| 2 |
Eagle Asset Management
St Petersburg,
Florida
|
+$10.4M |
| 3 |
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$8.55M |
| 4 |
BlackRock Fund Advisors
San Francisco,
California
|
+$5.8M |
| 5 |
SAM
Senzar Asset Management
New York
|
+$4.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$17.7M |
| 2 |
Hatteras Alternative Mutual Funds
Raleigh,
North Carolina
|
-$2.36M |
| 3 |
ICRM
Insight Capital Research & Management
Walnut Creek,
California
|
-$1.85M |
| 4 |
Bank of New York Mellon
New York
|
-$1.22M |
| 5 |
Granite Point Capital Management
Boston,
Massachusetts
|
-$1.14M |
ENTA Hedge Fund Activity: Q2 2014 in Review
99 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q2 2014, worth a combined $419M — up 24% from $340M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ENTA positions and 9 closed out — a net gain of 17 holders — while 46 added to existing stakes and 23 trimmed.
The largest buyer was Consonance Capital Management, adding an estimated $11.1M. The largest seller was Fidelity Investments, cutting an estimated $17.7M.
- 99 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q2 2014, up from 82 in Q1 2014.
- Funds reported $419M of Enanta Pharmaceuticals stock for Q2 2014, up 24% quarter-over-quarter.
- 26 funds opened new Enanta Pharmaceuticals positions in Q2 2014 and 9 closed out, a net change of +17 holders.
- The largest Enanta Pharmaceuticals buyer in Q2 2014 was Consonance Capital Management, an estimated $11.1M added.
- The largest Enanta Pharmaceuticals seller in Q2 2014 was Fidelity Investments, an estimated $17.7M sold.
Based on aggregated 13F filings for Q2 2014.